A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. METHODS: Induction consisted of idarubicin 12 mg/m(2) a day on days 1-3, c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jabbour, Elias, Kantarjian, Hagop, Ravandi, Farhad, Garcia-Manero, Guillermo, Estrov, Zeev, Verstovsek, Srdan, O’Brien, Susan, Faderl, Stefan, Thomas, Deborah A., Wright, John J., Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4061136/
https://ncbi.nlm.nih.gov/pubmed/20960519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25575
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados